ReviewBioscience reports2020
Gut microbiota in coronary artery disease: a friend or foe?
Review in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Clinical significance of gut microbiota-derived metabolite trimethylamine N-oxide in patients with systemic lupus erythematosus.Scientific reports · 2026Article
- The gut-heart axis: Exploring the role of the gut microbiome in cardiovascular health - A focused systematic review.American heart journal plus : cardiology research and practice · 2026Review
- The Role of the Gut Microbiota in Mental Health and Cognitive Function in Patients with Coronary Atherosclerosis.Nutrients · 2025Review
- Modified Zexie decoction improves phlegm-dampness type stage I hypertension by regulating the gut-immune-kidney axis.Frontiers in pharmacology · 2025Article
- Mucosal-associated invariant T cells correlate with myocardial ischaemia and remodelling in coronary artery disease.Clinical & translational immunology · 2025Article
- Gestational exposure to HIV drugs alters intestinal mucosa-associated microbial diversity in adult rat offspring.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Gut Microbiota and Its Metabolites: The Emerging Bridge Between Coronary Artery Disease and Anxiety and Depression?Aging and disease · 2024Review
- Microbiota of the gastrointestinal tract: Friend or foe?World journal of gastroenterology · 2023Review
- The role of the oral microbiome in smoking-related cardiovascular risk: a review of the literature exploring mechanisms and pathways.Journal of translational medicine · 2022Review
- Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis.Metabolites · 2022Review
- Coronary Artery Ectasia: Review of the Non-Atherosclerotic Molecular and Pathophysiologic Concepts.International journal of molecular sciences · 2022Review
- Article
- Skeletal Muscle Microvascular Dysfunction in Obesity-Related Insulin Resistance: Pathophysiological Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2022Review
- Gene-level metagenomic architectures across diseases yield high-resolution microbiome diagnostic indicators.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a growing interest in the role of gut microbiota in the pathophysiology of several diseases, including coronary artery diseases (CAD). Gut microorganisms may produce beneficial effects in myocardial ischemia either directly in the form of exogenous administration or indirectly by acting on fiber-rich food to produce important cardioprotective components. The harmful effects of gut microbiota in CAD are due to alteration in their composition with a significant decrease in Bacteroidetes and an increase in Firmicutes, Escherichia, Shigella, and Enterococcus. The altered microbiota may produce potentially toxic metabolites, including trimethylamine-N-oxide (TMAO). Indeed, the fasting plasma levels of TMAO are directly correlated to increased risk of major cardiovascular events in CAD patients, and it is proposed as a potential biomarker to predict the onset of major cardiovascular events. It is concluded that the change in the composition of gut microbiota in CAD patients may predispose to more harmful effects. However, exogenous delivery of probiotics may overcome the detrimental effects of myocardial ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.